|
|
|
||||||||||
Associate Professor Emeritus, Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown Medical School, Brown University, 174 Meeting St., Providence, RI 02912-9107, fax 401/863-1595, Ralph_Miech{at}brown.edu
Reprints: Dr. Miech
OBJECTIVE: To explain the role of mifepristone in medical abortions that results in fulminant and lethal septic shock due to Clostridium sordellii.
DATA SOURCES: MEDLINE, PubMed, and Google Scholar databases were searched (1984-March 2005). Key search terms were mifepristone, RU38486, RU486, Mifeprex, medical abortion, septic shock, innate immune system, cytokines, and Clostridium sordellii.
STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources were evaluated and all information deemed relevant was included for the information related to the development of the understanding of the pathophysiology of mifepristone-induced septic shock due to C. sordellii.
DATA SYNTHESIS: The mechanisms of action of mifepristone were incorporated into the pathophysiology of septic shock due to C. sordellii. Mifepristone, by blocking both progesterone and glucocorticoid receptors, interferes with the controlled release and functioning of cortisol and cytokines. Failure of physiologically controlled cortisol and cytokine responses results in an impaired innate immune system that results in disintegration of the body's defense system necessary to prevent the endometrial spread of C. sordellii infection. The abnormal cortisol and cytokine responses due to mifepristone coupled to the release of potent exotoxins and an endotoxin from C. sordellii are the major contributors to the rapid development of lethal septic shock.
CONCLUSIONS: Theoretically, it appears that the mechanisms of mifepristone action favor the development of infection that leads to septic shock and intensifies the actions of multiple inflammatory cytokines, resulting in fulminant, lethal septic shock.
Key Words: abortion, Clostridium sordellii, mifepristone, septic shock
Published Online, July 26, 2005. www.theannals.com, DOI 10.1345/aph.1G189
This article has been cited by other articles:
![]() |
D. M. Aronoff, Y. Hao, J. Chung, N. Coleman, C. Lewis, C. M. Peres, C. H. Serezani, G.-H. Chen, N. Flamand, T. G. Brock, et al. Misoprostol Impairs Female Reproductive Tract Innate Immunity against Clostridium sordellii J. Immunol., June 15, 2008; 180(12): 8222 - 8230. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P Miech Pathopharmacology of Excessive Hemorrhage in Mifepristone Abortions Ann. Pharmacother., December 1, 2007; 41(12): 2002 - 2007. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Geny, H. Khun, C. Fitting, L. Zarantonelli, C. Mazuet, N. Cayet, M. Szatanik, M.-C. Prevost, J.-M. Cavaillon, M. Huerre, et al. Clostridium sordellii Lethal Toxin Kills Mice by Inducing a Major Increase in Lung Vascular Permeability Am. J. Pathol., March 1, 2007; 170(3): 1003 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J Harrison and M. M Gary Authors' Reply Ann. Pharmacother., April 1, 2006; 40(4): 786 - 786. [Full Text] [PDF] |
||||
![]() |
M. M Gary and D. J Harrison Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient Ann. Pharmacother., February 1, 2006; 40(2): 191 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fischer, J. Bhatnagar, J. Guarner, S. Reagan, J. K. Hacker, S. H. Van Meter, V. Poukens, D. B. Whiteman, A. Iton, M. Cheung, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N. Engl. J. Med., December 1, 2005; 353(22): 2352 - 2360. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-i. Shukunami, K. Nishijima, F. Kotsuji, C. A. Grotegut, V. Dandolu, J. Zhang, M. D. Creinin, K. Barnhart, and the Management of Early Pregnancy Failure Trial Gr Medical vs. surgical management of early pregnancy failure. N. Engl. J. Med., December 1, 2005; 353(22): 2403 - 2404. [Full Text] [PDF] |
||||
![]() |
Pr. D. Sicard and Dr. L. Chauvelot-Moachon Comment: pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii Ann. Pharmacother., December 1, 2005; 39(12): 2142 - 2143. [Full Text] [PDF] |
||||